Milk protein allergy? This new drug is expected to solve the problem of patients
March 02, 2018 Source: WuXi PharmaTech
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Recently, DBV Technologies announced the positive results of Phase 2 clinical trials of its Viaskin Milk product for the treatment of IgE-mediated milk protein allergy patients (CMPA). The results showed that after 12 months, the children treated with Viaskin had significant desensitization effect on the milk. MILES (Effects and Safety of Milk) The age of children in the study ranged from 2 to 17 years old. They were divided into two groups, two to eleven years old, and twelve to seventeen years old.
Milk allergy is most common in children and affects 2% to 3% of the population. The range of reactions can vary from mild to severe. According to the Mayo Clinic, the most serious reactions can lead to allergic reactions. Milk allergy is different from milk intolerance. Milk or lactose intolerance usually shows symptoms different from true milk allergy, which may include hives, wheezing and vomiting.
During the MILES study, three doses of Viaskin Milk were tested on 198 patients to see which dose level of the drug was most effective. After analyzing the data, DBV determined that a medium dose of 300 micrograms was the most effective. The company also tested a dose of 150 micrograms and a dose of 500 micrograms. DBV intends to collect relevant data and discuss future related research with regulators. Viaskin Milk received the Fast Track Designation from the US FDA in September 2016. According to DBV, the data suggests that Viaskin Milk therapy is likely to be the first approved treatment for this type of allergy.
DBV's Viaskin is an electrostatic patch based on skin immunotherapy that activates the immune system by directly targeting the antigen presenting cells without allowing the antigen to enter the bloodstream, thereby applying the allergen directly to the skin.
â–² Dr. Stephen A. Tilles, Executive Director of the Asthma Clinical Research Center and Principal Investigator of MILES Research (Source: ASTHMA Inc. Clinical Research Center Official Website)
Dr. Stephen A. Tilles, Executive Director of the ASTHMA Inc. Clinical Research Center and Principal Investigator of MILES Research, said: "The results of this study are an important milestone for CMPA patients worldwide. We know that a small amount Milk protein may cause life-threatening reactions, and this disease has a profound negative impact on the quality of life of patients and their caregivers. Currently, there are no other research projects for this difficult disease. See these inspirations The efficacy and safety data of the human heart are exciting and the therapy is well tolerated."
â–² Dr. Hugh Sampson, Chief Scientific Officer of DBV Technologies (Source: DBV Technologies Official Website)
Dr. Hugh Sampson, Chief Scientific Officer of DBV Technologies, and Dr. Kurt Hirschhorn, Professor of Pediatrics at the Icahn School of Medicine in Sinai, said: "We would like to thank all of these patients, caregivers and researchers for participating in the Viaskin Milk trial. It is the second candidate for our Viaskin platform for the treatment of food allergies. These studies have brought us new insights into the unique immunotherapeutic properties and mechanisms of Viaskin Milk. We will continue to work hard to better understand Proper dosing regimen and optimal application configuration."
Dr. Sampson continued: "We look forward to discussing the next steps with the health department to further advance this important study, bringing potential treatment options to CMPA patients."
We wish that the research of Viaskin Milk will go smoothly and go public as soon as possible to bring the treatment gospel to patients.
Reference materials:
[1] DBV Technologies Reports Positive Data from Milk Allergy Tria
[2] DBV Technologies official website
GMP Certificated Immune Globulin Injection Supplier in China
Hepatitis B Immunoglobulin,Hep B Immunoglobulin,Hepatitis B Immunoglobulin Vaccine,Hepatitis Immune Globulin
FOSHAN PHARMA CO., LTD. , https://www.foshanmedicine.com